

RayBio[®] Label-based (L-Series) Human Antibody Array 1000

A combination of Human L-507 and Human L-493

Patent Pending Technology User Manual (Revised Dec 9, 2019)

For the simultaneous detection of the relative expression of 1000 human proteins in serum, plasma, cell culture supernatants, cell/tissue lysates or other body fluids.

**Human Array L-1000 (4) (4 Sample Kit)
Cat# AAH-BLG-1000-4**

**Human Array L-1000 (8) (8 Sample Kit)
Cat# AAH-BLG-1000-8**

**Please read manual carefully
before starting experiment**



Your Provider of Excellent Protein Array Systems and Services

**Tel: (Toll Free) 1-888-494-8555 or +1-770-729-2992; Fax: +1-770-206-2393;
Website: www.raybiotech.com Email: info@raybiotech.com**


TABLE OF CONTENTS

| | | |
|------|-------------------------------------------------------|----|
| I. | Introduction and How It Works..... | 2 |
| II. | Materials Provided..... | 3 |
| | A. Storage Recommendations..... | 3 |
| | B. Additional Materials Required..... | 3 |
| III. | Overview and General Considerations..... | 4 |
| | A. Preparation and Storage of Samples..... | 4 |
| | B. Handling the Glass Slides..... | 6 |
| | C. Layout of Human L-1000 Glass Slide..... | 7 |
| | D. Incubation and Washes..... | 7 |
| IV. | Protocol..... | 8 |
| | A. Dialysis of Sample..... | 8 |
| | B. Biotin Labeling of Sample..... | 9 |
| | C. Drying of the Glass Slide..... | 11 |
| | D. Blocking and Incubations..... | 11 |
| | E. Fluorescence Detection..... | 14 |
| V. | Antibody Array Maps and Target Lists..... | 15 |
| | A. RayBio Human Antibody Array L-507 Map..... | 15 |
| | B. RayBio Human Antibody Array L-507 Target List..... | 16 |
| | C. RayBio Human Antibody Array L-493 Map..... | 18 |
| | D. RayBio Human Antibody Array L-493 Target List..... | 19 |
| VI. | Interpretation of Results..... | 21 |
| | A. Explanation of Controls Spots..... | 21 |
| | B. Typical Results..... | 21 |
| | C. Background Subtraction..... | 23 |
| | D. Normalization of Array Data..... | 23 |
| | E. Threshold of Significant Difference..... | 24 |
| VII. | Troubleshooting Guide..... | 25 |

I. Introduction

Recent technological advances by RayBiotech have enabled the largest commercially available antibody array to date. With the L-Series 1000, researchers can now obtain a broad, panoramic view of cytokine expression. The expression levels of 1000 human target proteins can be simultaneously detected, including cytokines, chemokines, adipokines, growth factors, angiogenic factors, proteases, soluble receptors, soluble adhesion molecules and other proteins in cell culture supernatants, serum and plasma.

The first step in using the RayBio® L-Series Human Antibody Array 1000 is to biotinylate the primary amine groups of the proteins in your sample (sera or plasma, cell culture supernatants, cell lysates or tissue lysates). The glass slide arrays are then blocked, just like a Western blot, and the biotin-labeled sample is added onto the glass slide, which is pre-printed with capture antibodies. The slide is incubated to allow binding of target proteins. Streptavidin-conjugated fluorescent dye (Cy3 equivalent) is then applied to the array. Finally, the glass slide is dried, and laser fluorescence scanning is used to visualize signals.



II. Materials Provided

A. Storage Recommendations

Upon receipt, the kit should be stored at -20°C until needed. Use within 6 months from the date of shipment is recommended. After initial use, remaining reagents should be stored at 4°C and may be stored for up to 3 months (Labeling Reagent, Item B, should be prepared fresh each time before use). Unused glass slides should be kept at -20 °C and repeated freeze-thaw cycles should be avoided (slides may be stored for 6 months).

| ITEM | DESCRIPTION | Cat# AAH-BLG-1000-4 | Cat# AAH-BLG-1000-8 |
|------|------------------------------------------------------------|---------------------|----------------------|
| A | Dialysis Vials & Floating Dialysis Rack | 8 vials | 16 vials |
| B | Labeling Reagent | 2 vials | 4 vials |
| D | Stop Solution | 1 vial (50 µl) | |
| E | RayBio® L-Series Human Antibody Array L-1000 Glass Slides* | 1 L-507 slide | 2 L-507 slides |
| | | 1 L-493 slide | 2 L-493 slides |
| F | Blocking Buffer | 2 bottles (8 ml/ea) | 4 bottles (8 ml/ea) |
| G | 20X Wash Buffer I | 1 bottle (30 ml) | 2 bottles (30 ml/ea) |
| H | 20X Wash Buffer II | 1 bottle (30 ml) | 2 bottles (30 ml/ea) |
| I | Cy3-Conjugated Streptavidin | 1 vial | 2 vials |
| J | Adhesive Plastic Strips | | |
| K | Labeling Buffer | 1 bottle (8 ml) | |
| n/a | 2X Cell Lysis Buffer** | 1 bottle (10 ml) | |
| M | 30 ml Centrifuge Tube | 1 tube | |

* Each slide contains 4 identical subarrays

** Only needed if testing cell or tissue lysates

B. Additional Materials Required

- KCl, NaCl, KH₂PO₄, Na₂HPO₄ and ddH₂O
- 1 ml tube, small plastic or glass containers
- Orbital shaker or oscillating rocker
- Beaker, stir plate and stir bar
- Pipettors, pipette tips and other common lab consumables
- Laser scanner for fluorescence detection (list available online)
- Aluminum foil

III. Overview and General Considerations

A. Preparation and Storage of Samples

1) Preparation of Cell Culture Supernatants

1. Seed cells at a density of 1×10^6 cells in 100 mm tissue culture dishes.*
2. Culture cells in complete culture medium for ~24–48 hours.**
3. Replenish with serum-free or low-serum medium such as 0.2% FCS/FBS serum, and then incubate cells again for ~48 hours.**,[†] The membrane-based array is recommended if high serum medium such as 10% FCS/FBS is used, as high background can occur on glass slide arrays with high serum containing media samples.
4. To collect supernatants, centrifuge at 1,000 g for 10 min and store as ≤ 1 ml aliquots at -80°C until needed.
5. Measure the total wet weight of cultured cells in the pellet and/or culture dish. You may then normalize between arrays by dividing fluorescent signals by total cell mass (i.e., express results as the relative amount of protein expressed/mg total cell mass). Or you can normalize between arrays by determining cell lysate concentration using a total protein assay (BCA Protein Assay Kit, Pierce, Prod #: 23227).

**The density of cells per dish used is dependent on the cell type. More or less cells may be required.*

***Optimal culture time may vary and will depend on the cell line, treatment conditions and other factors.*

[†]Bovine serum proteins produce detectable signals on the RayBio[®] L-Series Array in media containing serum concentrations as low as 0.2%. When testing serum-containing media, we strongly recommend testing an uncultured media blank for comparison with sample results.

2) Extracting Protein from Cells

1. Centrifuge Cells:

a. Adherent Cells:

- i. Remove supernatant from cell culture and wash cells gently twice with cold 1X PBS taking care not to disturb cell layer.
- ii. Add enough cold 1X PBS to cover cell layer and use cell scraper to detach cells. Proceed to b. Cells in Suspension.

b. Cells in Suspension: Pellet the cells by centrifuging using a microcentrifuge at 1500 rpm for 10 min.

2. Make sure to remove any remaining PBS before adding 1X Cell Lysis Buffer (2X Cell Lysis Buffer should be diluted 2 fold with ddH₂O). Solubilize the cells at 2×10^7 cells/ml in 1X Cell Lysis Buffer.
3. Pipette up and down to resuspend cells and rock the lysates gently at 2–8 °C for 30 minutes. Transfer extracts to microfuge tubes and centrifuge at 13,000 rpm for 10 min at 2-8 °C.

Note: If the lysates appear to be cloudy, transfer the lysates to a clean tube, centrifuge again at 13,000 rpm for 20 minutes at 2-8°C. If the lysates are still not clear, store them at -20°C for 20 minutes. Remove from the freezer and immediately centrifuge at 13,000 rpm for 20 minutes at 2-8°C.

4. Transfer lysates to a clean tube. Determining cell lysate concentrations using a total protein assay (BCA Protein Assay Kit, Pierce, Prod# 23227). Aliquot the lysates and store at -80°C.

3) Extracting Protein from Crude Tissue

1. Transfer approximate 100 mg crude tissue into a tube with 1 ml 1X Cell Lysis Buffer (2X Cell Lysis Buffer should be diluted 2-fold with ddH₂O).
2. Homogenize the tissue according to homogenizer manufacturer instructions.

3. Transfer extracts to microcentrifuge tubes and centrifuge for 20 min at 13,000 rpm (4°C).

Note: If the supernatant appears to be cloudy, transfer the supernatants to a clean tube, centrifuge again at 13,000 rpm for 20 minutes at 2-8°C. If the supernatant is still not clear, store the lysate at -20°C for 20 minutes. Remove from the freezer, immediately centrifuge at 13,000 rpm for 20 minutes at 2-8°C.

4. Transfer supernatant to a clean tube and store at -80°C.


B. Handling the Glass Slides

- The microarray slides are delicate. Please do not touch the array surface with pipette tips, forceps or your fingers. Hold the slides by the edges only.
- Handle the slides with powder-free gloves and in a clean environment.
- Do not remove the glass slide from the chamber assembly until step 20 on page 14, and take great care not to break the glass slide when doing so.
- Permanent marker ink can significantly interfere with fluorescent signal detection. Never mark anywhere on the front (arrayed) side of the slide. It's best to avoid using marker completely, however if you need to number the slide, please add a small mark only on the back of the slide along the top or bottom edge using a green or blue ultra-fine point Sharpie® brand marker, only after the slide is completely dry.
- Remove reagents/sample by gently applying suction with a pipette to corners of each chamber. Do not touch the printed area of the array, only the sides as seen in image below.



C. Layout of Human L-507 and L-493 Glass Slide

4 identical sub-arrays on one slide



4 printed sub-arrays per glass chip

D. Incubations and Washes


- Cover incubation chamber with a Plastic Adhesive Strip (Item J) to prevent evaporation during incubation or wash steps, particularly those steps lasting 2 hours or longer.
- During incubation and wash steps avoid foaming and remove all bubbles from the sub-array surface.
- Perform all incubation and wash steps under gentle rotation or rocking motion (~0.5 to 1 cycle/sec).
- Wash steps in Wash Buffer II and all incubation steps may be performed overnight at 4°C.

- Avoid cross-contamination of samples to neighboring wells. To remove Wash Buffers and other reagents from chamber wells, you may invert the Glass Slide Assembly to decant, and aspirate the remaining liquid.
- Unlike most Cy3 fluors, the streptavidin-conjugated fluor used in this kit is very stable at room temperature (RT) and resistant to photobleaching on the hybridized glass slides. However, please protect glass slides from directly strong light and temperatures above RT.


IV. Protocol

Assay Diagram

1. Cell culture supernatants or cell/tissue lysates.



2. Serum or plasma



Note: If using cell or tissue lysates, start at "Dialysis of sample"

A. Dialysis of Sample

Note: Samples must be dialyzed prior to biotin-labeling (Steps 5–7).

1. To prepare dialysis buffer (1X PBS, pH=8.0), dissolve 0.6 g KCl, 24 g NaCl, 0.6 g KH₂PO₄ and 3.45 g Na₂HPO₄ in 2500 ml ddH₂O. Adjust pH=8.0 with 1M NaOH and adjust final volume to 3000 ml with ddH₂O.
2. Add each sample into a separate Dialysis Tube (Item A). Loading volumes are as follows: 200 µl cell culture supernatant; 100 µl cell or tissue lysate (1~2 mg/ml total protein); 20 µl serum or plasma + 80 µl dialysis buffer (5-fold dilution). Carefully place Dialysis Tubes into Floating Dialysis Rack.

Note for cell culture supernatants: if using a 2-fold dilution of biotin-labeled sample in the array incubation step (page 11, step 11), you will need to load a total of 400 µl of original cell culture supernatant into 2 separate Dialysis Tubes (200 µl /tube).

Note: If the samples appear to be cloudy, transfer the samples to a clean tube, centrifuge at 13,000 rpm for 20 minutes at 2-8°C. If the samples are still not clear, store them at -20°C for 20 minutes. Remove from the freezer, immediately centrifuge at 13,000 rpm for 20 minutes at 2-8°C.

3. Place Floating Dialysis Rack into ≥500 ml dialysis buffer in a large beaker. Place beaker on a stir plate and dialyze, for at least 3 hours at 4°C, stirring buffer gently. Then exchange the dialysis buffer and repeat dialysis for at least 3 hours at 4°C. Transfer dialyzed sample to a clean microfuge tube. Spin dialyzed samples for 5 minutes at 10,000 rpm to remove any particulates or precipitates, and then transfer the supernatants to a clean tube.

Note: The sample volume may change during dialysis.

Note: Dialysis procedure may proceed overnight.

Note: Determine the total protein concentration for cell culture supernatants or cell/tissue lysate after dialysis procedure (Step 3). We recommended using a BCA total protein assay (eg, Pierce, Catalog # 23227).

B. Biotin-labeling Sample

Note: Amines (e.g., Tris, glycine) and azides quench the biotinylation reaction. Avoid contaminating samples with these chemicals prior to biotinylation.

4. Immediately before use, prepare 1X Labeling Reagent. Briefly spin down the Labeling Reagent tube (Item B). Add 100 μ l 1X PBS into the tube, then pipette up and down or vortex slightly to dissolve the lyophilized reagent.
5. Add 1X Labeling Reagent to dialyzed samples.
 - a. For labeling cell culture supernatants: transfer 180 μ l dialyzed sample into a new tube. Add 36 μ l of 1X Labeling Reagent Solution per 1 mg total protein in dialyzed cell culture supernatant. Mix well. For example, if sample's total protein concentration is 0.5 mg/ml you need to add 3.24 μ l 1X Labeling Reagent to the tube of 180 μ l dialyzed sample.

Note: You need to biotin-label 360 μ l of dialyzed sample if dilution of the biotin-labeled samples is 2 fold in step 11 on page 11.

- b. For labeling serum or plasma: Add 22 μ l of 1X Labeling Reagent Solution into a new tube containing 35 μ l dialyzed serum or plasma sample and 155 μ l Labeling Buffer (Item K).
- c. For labeling cell or tissue lysates: transfer 30 μ g (e.g. 15 μ l of 2 mg/ml) cell or tissue lysates into a tube and add labeling buffer (Item K) for a total volume of 260 μ l. Then add 3.3 μ l of 1X Labeling Reagent Solution.

Note: To normalize serum/plasma concentrations during biotinylation, measure sample volume before and after dialysis. Then adjust the volumes of dialyzed serum/plasma and Labeling Buffer to compensate.

For example, if the sample volume doubles after dialysis, then use twice as much serum/plasma in the labeling reaction (70 μ l) and reduce the Labeling Buffer to 120 μ l.

6. Incubate the reaction solution at RT with gentle rocking or shaking for 30 minutes. Mix the reaction solution by gently tapping the tube every 5 minutes.
7. Add 3 μ l Stop Solution (Item D) into each reaction tube. Collect and transfer each sample from reaction tube into a separate Dialysis Tube (Item A). Immediately dialyse samples as directed in Step 3 on pages 9.

Note: Biotinylated samples can be stored at -20°C or -80°C until you are ready to proceed with the assay.

C. Drying the Glass Slide

8. Remove the package containing the Assembled Glass Slide (Item E) from the freezer. Place unopened package on the bench top for approx. 15 minutes, and allow the Assembled Glass Slide to equilibrate to RT.
9. Open package, and take the Assembled Glass Slide out of the sleeve (Do not disassemble the Glass Slide from the chamber assembly). Place glass slide assembly in laminar flow hood or similar clean environment for 1-2 hours at RT.

Note: Protect the slide from dust or other contaminants.

D. Blocking and Incubations

Note: Glass slide should be completely dry before adding Blocking Buffer to wells.

10. Block sub-arrays by adding 400 μ l of Blocking Buffer (Item F) into each well of Assembled Glass Slide and incubating at RT for 30 minutes. Ensure there are no bubbles on the array surfaces.
11. Immediately prior to sample incubation, spin biotin-labeled samples for 5 minutes at 10,000 rpm to remove any particulates or

precipitates. Dilute samples with Blocking Buffer. Recommended dilution of the biotin-labeled samples with Blocking Buffer is 2-10 fold for cell culture supernatants, 20-fold for serum/plasma and 30 fold cell/tissue lysate.

Note: Optimal sample dilution factor will depend on the abundance of target proteins. If the background or antigen-specific antibody signals are too strong, the sample can be diluted further in subsequent experiments. If the signal is too weak, more concentrated samples can be used.

12. Completely remove Blocking Buffer from each well. Add 400 μ l of diluted samples into appropriate wells. Remove any bubbles on array surfaces. Incubate arrays with gentle rocking or shaking for 2 hours at RT or overnight at 4°C.

Note: Avoid the flow of sample into neighboring wells.

13. Based on number of samples and remaining protocol calculate the amount of 1X Wash Buffer I and 1X Wash Buffer II needed to complete the experiment. Separately dilute the required amounts of 20X Wash Buffer I Concentrate (Item G) 20-fold and 20X Wash Buffer II Concentrate (Item H) with ddH₂O.
14. Decant the samples from each well, and wash 3 times with 800 μ l of 1X Wash Buffer I at RT with gentle rocking or shaking for 5 min per wash.
15. Obtain a clean container (e.g., pipette tip box or slide-staining jar), place the Assembled Glass Slide into the container with enough volume of 1X Wash Buffer I to completely cover the entire assembly, and remove any bubbles in wells. Wash 2 times at RT with gentle rocking or shaking for 10 min per wash.
16. Decant the Wash Buffer I from each well, place the Assembled Glass Slide into the container with enough volume of 1X Wash Buffer II to completely cover the entire assembly, and remove any bubbles in wells. Wash 2 times at RT with gentle rocking or shaking for 5 min per wash.

17. Prepare 1X Cy3-Conjugated Streptavidin:
- a) Briefly spin down tube containing the Cy3-Conjugated Streptavidin (Item I) immediately before use.
 - b) Add 1000 μ l of Blocking Buffer into the tube to prepare a concentrated Cy3-Conjugated Streptavidin stock solution. Pipette up and down to mix gently (do not store the stock solution for later use).
 - c) To prepare 1X Cy3-Conjugated Streptavidin add 200 μ l of the concentrated Cy3-Conjugated Streptavidin stock solution into a tube with 800 μ l of Blocking Buffer. Mix gently.
18. Carefully remove Assembled Glass Slide from container. Remove all of Wash Buffer II from the wells. Add 400 μ l of 1X Cy3-Conjugated Streptavidin to each sub-array. Cover the incubation chamber with the plastic adhesive strips.


Note: Avoid exposure to light in Steps 19–25 by covering the Glass Slide Assembly with aluminum foil or incubate in a dark room.

19. Incubate with 1X Cy3-Conjugated Streptavidin at RT for 2 hours with gentle rocking or shaking.

Note: Incubation may be done overnight at 4°C.

20. Decant the solution and disassemble the glass slide from the incubation frame and chamber. Disassemble the device by pushing clips outward from the side, as shown below. Carefully remove the glass slide from the gasket.

Note: Be careful not to touch the printed surface of the glass slide, which is on the same side as the barcode.



21. Gently place the glass slide into 30 ml Centrifuge Tube (Item M). Add enough 1X Wash Buffer I to cover the entire glass slide (about 30 ml).

Wash with gentle rocking or shaking for 10 min. Remove the wash buffer. Repeat 2 times for a total of 3 washes.

22. Repeat step 20, this time with 1X Wash Buffer II. Repeat one time for a total of two washes for 5 min per wash.
23. Finally, wash the glass slide with 30 ml of ddH₂O for 5 min. Remove glass slide and decant water from Centrifuge Tube.
24. Remove buffer droplets from the slide completely by one of the following ways:

Put the glass slides in a laminar flow hood for 20 minutes or until slide is completely dry.

- Or, dry the glass slide by a compressed N₂ stream.
- Or gently apply suction with a pipette to remove buffer droplets. Do not touch the array, only the sides.

Note: Make sure the finished glass slide is completely dry before scanning or storage.


E. Fluorescence Detection

25. You may proceed immediately to scanning or you may store the slide at -20 °C in the Centrifuge Tube provided or at RT and to scan at a later time.

Note: Unlike most Cy3 fluors, the Streptavidin-Conjugated Fluor used in this kit is very stable at RT and resistant to photobleaching on completed glass slides. However, please protect glass slides from temperatures above RT and store them in the dark. Do not expose glass slide to strong light, such as sunlight or a UV lamp.

Note: If you need to repeat any of the incubation steps after finishing the experiment, you must first re-assemble the glass slide into the incubation chamber by following the steps as described below. To avoid breaking the printed glass slide, you may first want to practice assembling the device with a blank glass slide.

1. Apply slide to incubation chamber barcode facing upward (image A).
2. Gently snap one edge of a snap-on side (image B).
3. Gently press other of side against lab bench and push in lengthwise direction (image C).
4. Repeat with the other side (image D)



B. RayBio Human Antibody Array L-507 Target List

| Number | Name | Number | Name | Number | Name | Number | Name | Number | Name |
|--------|--------------------------|--------|----------------------------------------|--------|--------------------|--------|------------------------|--------|-------------------------|
| 1 | Positive 1a | 61 | CCR7 | 121 | Eotaxin-2 / MPIF-2 | 181 | GFR alpha-2 | 241 | IL-1 R6 / IL-1 Rrp2 |
| 2 | Positive 2a | 62 | CCR8 | 122 | Eotaxin-3 / CCL26 | 182 | GFR alpha-3 | 242 | IL-1 R8 |
| 3 | Positive 3a | 63 | CCR9 | 123 | Epregrulin | 183 | GFR alpha-4 | 243 | IL-1 R9 |
| 4 | neg | 64 | CD14 | 124 | ErbB2 | 184 | GITR / TNFRF18 | 244 | IL-1 ra |
| 5 | 6Ckine | 65 | CD27 / TNFRSF7 | 125 | ErbB3 | 185 | GITR Ligand / TNFSF18 | 245 | IL-1 sRI |
| 6 | Activin A | 66 | CD30 / TNFRSF8 | 126 | ErbB4 | 186 | Glucagon | 246 | IL-1 sRII |
| 7 | Activin B | 67 | CD30 Ligand / TNFSF8 | 127 | Erythropoietin | 187 | Glut1 | 247 | IL-2 |
| 8 | Activin C | 68 | CD40 / TNFRSF5 | 128 | E-Selectin | 188 | Glut2 | 248 | IL-2 R alpha |
| 9 | Activin RIA / ALK-2 | 69 | CD40 Ligand / TNFSF5 / CD154 | 129 | FADD | 189 | Glut3 | 249 | IL-2 R beta / CD122 |
| 10 | Activin RIB / ALK-4 | 70 | CD 163 | 130 | FAM3B | 190 | Glut5 | 250 | IL-2 R gamma |
| 11 | Activin RII A/B | 71 | Cerberus 1 | 131 | Fas / TNFRSF6 | 191 | Glypican 3 | 251 | IL-3 |
| 12 | Activin RIIA | 72 | Chem R23 | 132 | Fas Ligand | 192 | Glypican 5 | 252 | IL-3 R alpha |
| 13 | Adiponectin / Acrp30 | 73 | Chordin-Like 1 | 133 | FGF Basic | 193 | GM-CSF | 253 | IL-4 |
| 14 | AgRP | 74 | Chordin-Like 2 | 134 | FGF-BP | 194 | GM-CSF R alpha | 254 | IL-4 R |
| 15 | ALCAM | 75 | CLC | 135 | FGF R3 | 195 | Granzyme A | 255 | IL-5 |
| 16 | Angiogenin | 76 | CNTF | 136 | FGF R4 | 196 | GREMLIN | 256 | IL-5 R alpha |
| 17 | Angiopoietin-1 | 77 | CNTF R alpha | 137 | FGF R5 | 197 | GRO | 257 | IL-6 |
| 18 | Angiopoietin-2 | 78 | Coagulation Factor III / Tissue Factor | 138 | FGF-4 | 198 | GRO-a | 258 | IL-6 R |
| 19 | Angiopoietin-4 | 79 | CRIM 1 | 139 | FGF-5 | 199 | Growth Hormone (GH) | 259 | IL-7 |
| 20 | Angiopoietin-like 1 | 80 | Cripto-1 | 140 | FGF-6 | 200 | Growth Hormone R (GHR) | 260 | IL-7 R alpha |
| 21 | Angiopoietin-like 2 | 81 | CRTH-2 | 141 | FGF-7 / KGF | 201 | HB-EGF | 261 | IL-8 |
| 22 | Angiopoietin-like Factor | 82 | Cryptic | 142 | FGF-8 | 202 | HCC-4 / CCL16 | 262 | IL-9 |
| 23 | Angiostatin | 83 | Csk | 143 | FGF-9 | 203 | HCR / CRAM-A/B | 263 | IL-10 |
| 24 | APJ | 84 | CTACK / CCL27 | 144 | FGF-10 / KGF-2 | 204 | Hepassocin | 264 | IL-10 R alpha |
| 25 | APRIL | 85 | CTGF / CCN2 | 145 | FGF-11 | 205 | GLO-1 | 265 | IL-10 R beta |
| 26 | AR (Amphiregulin) | 86 | CTLA-4 / CD152 | 146 | FGF-12 | 206 | HGF | 266 | IL-11 |
| 27 | Artemin | 87 | CV-2 / Crossveinless-2 | 147 | FGF-13 1B | 207 | HGFR | 267 | IL-12 p40 |
| 28 | Axl | 88 | CXCL14 / BRAK | 148 | FGF-16 | 208 | HRG-alpha | 268 | IL-12 p70 |
| 29 | B7-1 / CD80 | 89 | CXCL16 | 149 | FGF-17 | 209 | HRG-beta 1 | 269 | IL-12 R beta 1 |
| 30 | BAFF R / TNFRSF13C | 90 | CXCR1 / IL-8 RA | 150 | FGF-18 | 210 | HVEM / TNFRSF14 | 270 | IL-12 R beta 2 |
| 31 | BCMA / TNFRSF17 | 91 | CXCR2 / IL-8 RB | 151 | FGF-19 | 211 | I-309 | 271 | IL-13 |
| 32 | BD-1 | 92 | CXCR3 | 152 | FGF-20 | 212 | ICAM-1 | 272 | IL-13 R alpha 1 |
| 33 | BDNF | 93 | CXCR4 (fusin) | 153 | FGF-21 | 213 | ICAM-2 | 273 | IL-13 R alpha 2 |
| 34 | beta-Catenin | 94 | CXCR5 / BLR-1 | 154 | FGF-23 | 214 | ICAM-3 (CD50) | 274 | IL-15 |
| 35 | BAX | 95 | CXCR6 | 155 | FLRG | 215 | ICAM-5 | 275 | IL-15 R alpha |
| 36 | beta-NGF | 96 | D6 | 156 | Flt-3 Ligand | 216 | IFN-alpha / beta R1 | 276 | IL-16 |
| 37 | BK1 | 97 | DAN | 157 | Follistatin | 217 | IFN-alpha / beta R2 | 277 | IL-17 |
| 38 | BLC / BCA-1 / CXCL13 | 98 | DANCE | 158 | Follistatin-like 1 | 218 | IFN-beta | 278 | IL-17B |
| 39 | BMP-2 | 99 | DcR3 / TNFRSF6B | 159 | Fractalkine | 219 | IFN-gamma | 279 | IL-17B R |
| 40 | BMP-3 | 100 | Decorin | 160 | Frizzled-1 | 220 | IFN-gamma R1 | 280 | IL-17C |
| 41 | BMP-3b / GDF-10 | 101 | Dkk-1 | 161 | Frizzled-3 | 221 | IGFBP-1 | 281 | IL-17D |
| 42 | BMP-4 | 102 | Dkk-3 | 162 | Frizzled-4 | 222 | IGFBP-2 | 282 | IL-17E |
| 43 | BMP-5 | 103 | Dkk-4 | 163 | Frizzled-5 | 223 | IGFBP-3 | 283 | IL-17F |
| 44 | BMP-6 | 104 | DR3 / TNFRSF25 | 164 | Frizzled-6 | 224 | IGFBP-4 | 284 | IL-17R |
| 45 | BMP-7 | 105 | DR6 / TNFRSF21 | 165 | Frizzled-7 | 225 | IGFBP-6 | 285 | IL-17RC |
| 46 | BMP-8 | 106 | Dkk | 166 | Galectin-3 | 226 | IGFBP-rp1 / IGFBP-7 | 286 | Positive 1b |
| 47 | BMP-15 | 107 | EDA-A2 | 167 | GASP-1 / WFIKKNRP | 227 | IGF-I | 287 | Positive 2b |
| 48 | BMPR-IA / ALK-3 | 108 | EDAR | 168 | GASP-2 / WFIKKN | 228 | IGF-I SR | 288 | Positive 3b |
| 49 | BMPR-IB / ALK-6 | 109 | EDG-1 | 169 | GCP-2 / CXCL6 | 229 | IGF-II | 289 | neg |
| 50 | BMPR-II | 110 | EGF | 170 | GCSF | 230 | IGF-II R | 290 | IL-17RD |
| 51 | BTC | 111 | EGF R / ErbB1 | 171 | G-CSF R / CD 114 | 231 | IL-1 alpha | 291 | IL-18 BPa |
| 52 | Cardiotrophin-1 / CT-1 | 112 | EG-VEGF / PK1 | 172 | GDF1 | 232 | IL-1 beta | 292 | IL-18 R alpha / IL-1 R5 |
| 53 | CCL14 / HCC-1 / HCC-3 | 113 | EMAP-II | 173 | GDF3 | 233 | IL-1 F5 / FIL1delta | 293 | IL-18 R beta / AcPL |
| 54 | CCL28 / VIC | 114 | ENA-78 | 174 | GDF5 | 234 | IL-1 F6 / FIL1 epsilon | 294 | IL-19 |
| 55 | CCR1 | 115 | Endocan | 175 | GDF8 | 235 | IL-1 F7 / FIL1 zeta | 295 | IL-20 |
| 56 | CCR2 | 116 | Endoglin / CD105 | 176 | GDF9 | 236 | IL-1 F8 / FIL1 eta | 296 | IL-20 R alpha |
| 57 | CCR3 | 117 | Endostatin | 177 | GDF11 | 237 | IL-1 F9 / IL-1 H1 | 297 | IL-20 R beta |
| 58 | CCR4 | 118 | Endothelin | 178 | GDF-15 | 238 | IL-1 F10 / IL-1HY2 | 298 | IL-21 |
| 59 | CCR5 | 119 | EN-RAGE | 179 | GDNF | 239 | IL-1 R3 / IL-1 R AcP | 299 | IL-21 R |
| 60 | CCR6 | 120 | Eotaxin / CCL11 | 180 | GFR alpha-1 | 240 | IL-1 R4 / ST2 | 300 | IL-22 |

RayBio Human Antibody Array L-507 Target List... continued

| Number | Name | Number | Name | Number | Name | Number | Name |
|--------|------------------------------|--------|-----------------------------|--------|---------------------------------|--------|----------------------------|
| 301 | IL-22 BP | 361 | MMP-2 | 421 | RANK / TNFRSF11A | 481 | TMEFF1 / Tomoregulin-1 |
| 302 | IL-22 R | 362 | MMP-3 | 422 | RANTES | 482 | TMEFF2 |
| 303 | IL-23 | 363 | MMP-7 | 423 | RELM beta | 483 | TNF-alpha |
| 304 | IL-23 R | 364 | MMP-8 | 424 | RELT / TNFRSF19L | 484 | TNF-beta |
| 305 | IL-24 | 365 | MMP-9 | 425 | ROBO4 | 485 | TNF RI / TNFRSF1A |
| 306 | IL-26 | 366 | MMP-10 | 426 | S100 A8/A9 | 486 | TNF RII / TNFRSF1B |
| 307 | IL-27 | 367 | MMP-11 / Stromelysin-3 | 427 | S100A10 | 487 | TRADD |
| 308 | IL-28A | 368 | MMP-12 | 428 | SAA | 488 | TRAIL / TNFSF10 |
| 309 | IL-29 | 369 | MMP-13 | 429 | SCF | 489 | TRAIL R1 / DR4 / TNFRSF10A |
| 310 | IL-31 | 370 | MMP-14 | 430 | SCF R / CD117 | 490 | TRAIL R2 / DR5 / TNFRSF10B |
| 311 | IL-31 RA | 371 | MMP-15 | 431 | SDF-1 / CXCL12 | 491 | TRAIL R3 / TNFRSF10C |
| 312 | BACE-1 | 372 | MMP-16 / MT3-MMP | 432 | sFRP-1 | 492 | TRAIL R4 / TNFRSF10D |
| 313 | FACX | 373 | MMP-19 | 433 | sFRP-3 | 493 | TRANCE |
| 314 | Insulin | 374 | MMP-20 | 434 | sFRP-4 | 494 | TREM-1 |
| 315 | Insulin R | 375 | MMP-24 / MT5-MMP | 435 | sgp130 | 495 | TROY / TNFRSF19 |
| 316 | Insulysin / IDE | 376 | MMP-25 / MT6-MMP | 436 | SIGIRR | 496 | TSG-6 |
| 317 | IP-10 | 377 | MSP alpha Chain | 437 | Siglec-5/CD170 | 497 | TSLP R |
| 318 | I-TAC / CXCL11 | 378 | Musk | 438 | Siglec-9 | 498 | TWEAK / TNFSF12 |
| 319 | Kininostatin / kininogen | 379 | NAP-2 | 439 | SLPI | 499 | TWEAK R / TNFRSF12 |
| 320 | Kremen-1 | 380 | NCAM-1 / CD56 | 440 | Smad 1 | 500 | Ubiquitin+1 |
| 321 | Kremen-2 | 381 | Neuritin | 441 | Smad 4 | 501 | uPA |
| 322 | Latent TGF-beta bp1 | 382 | NeuroD1 | 442 | Smad 5 | 502 | uPAR |
| 323 | LBP | 383 | Neuropilin-2 | 443 | Smad 7 | 503 | Vasorin |
| 324 | Lck | 384 | Neurturin | 444 | Smad 8 | 504 | VCAM-1 (CD106) |
| 325 | LECT2 | 385 | NGF R | 445 | Prdx6 | 505 | VE-Cadherin |
| 326 | Lefty - A | 386 | Nidgen-1 | 446 | Soggy-1 | 506 | VEGF |
| 327 | Leptin (OB) | 387 | NOV / CCN3 | 447 | Sonic Hedgehog (Shh N-terminal) | 507 | VEGF R2 (KDR) |
| 328 | Leptin R | 388 | NrCAM | 448 | SPARC | 508 | VEGF R3 |
| 329 | LFA-1 alpha | 389 | NRG1 Isoform GGF2 | 449 | Spinesin | 509 | VEGF-B |
| 330 | LIF | 390 | NRG2 | 450 | TAC1 / TNFRSF13B | 510 | VEGF-C |
| 331 | LIF R alpha | 391 | NRG3 | 451 | Tarc | 511 | VEGF-D |
| 332 | LIGHT / TNFSF14 | 392 | NT-3 | 452 | TCCR / WSX-1 | 512 | VEGI / TNFSF15 |
| 333 | Lipocalin-1 | 393 | NT-4 | 453 | TECK / CCL25 | 513 | WIF-1 |
| 334 | Lipocalin-2 | 394 | Orexin A | 454 | TFPI | 514 | WISP-1 / CCN4 |
| 335 | LRP-1 | 395 | Orexin B | 455 | TGF-alpha | 515 | XEDAR |
| 336 | LRP-6 | 396 | OSM | 456 | TGF-beta 1 | 516 | Neg |
| 337 | L-Selectin (CD62L) | 397 | Osteoactivin / GPNMB | 457 | TGF-beta 2 | 517 | Neg |
| 338 | Lymphotactin / XCL1 | 398 | Osteocrin | 458 | TGF-beta 3 | 518 | Neg |
| 339 | Lymphotoxin beta / TNFSF3 | 399 | Osteoprotegerin / TNFRSF11B | 459 | TGF-beta 5 | 519 | Neg |
| 340 | Lymphotoxin beta R / TNFRSF3 | 400 | OX40 Ligand / TNFSF4 | 460 | TGF-beta RI / ALK-5 | 520 | Neg |
| 341 | MAC-1 | 401 | PARC / CCL18 | 461 | TGF-beta RII | 521 | Neg |
| 342 | MCP-1 | 402 | PD-ECGF | 462 | Grb2 | 522 | Neg |
| 343 | MCP-2 | 403 | PDGF R alpha | 463 | TGF-beta RIII | 523 | P-3c |
| 344 | MCP-3 | 404 | PDGF R beta | 464 | Thrombopoietin (TPO) | 524 | P-2c |
| 345 | MCP-4 / CCL13 | 405 | PDGF-AA | 465 | TPX | 525 | P-1c |
| 346 | M-CSF | 406 | PDGF-AB | 466 | Thrombospondin-1 | | |
| 347 | M-CSF R | 407 | PDGF-BB | 467 | Thrombospondin-2 | | |
| 348 | MDC | 408 | PDGF-C | 468 | Thrombospondin-4 | | |
| 349 | MFG-E8 | 409 | PDGF-D | 469 | Thymopoietin | | |
| 350 | MFRP | 410 | PECAM-1 / CD31 | 470 | Tie-1 | | |
| 351 | MICA | 411 | Pentraxin3 / TSG-14 | 471 | Tie-2 | | |
| 352 | MIF | 412 | Persephin | 472 | TIMP-1 | | |
| 353 | MIG | 413 | PF4 / CXCL4 | 473 | TIMP-2 | | |
| 354 | MIP-1a | 414 | PIGF | 474 | TIMP-3 | | |
| 355 | MIP-1b | 415 | PLUNC | 475 | TIMP-4 | | |
| 356 | MIP-1d | 416 | Pref-1 | 476 | TL1A / TNFSF15 | | |
| 357 | MIP 2 | 417 | Progranulin | 477 | TLR1 | | |
| 358 | MIP-3 alpha | 418 | Prolactin | 478 | TLR2 | | |
| 359 | MIP-3 beta | 419 | P-selectin | 479 | TLR3 | | |
| 360 | MMP-1 | 420 | RAGE | 480 | TLR4 | | |

D. RayBio Human Antibody Array L-493 Target List

| Number | Name | Number | Name | Number | Name | Number | Name | Number | Name |
|--------|-------------------|--------|-----------------|--------|---------------------------------|--------|------------------|--------|------------------|
| 1 | Positive-1a | 61 | ApoE3 | 121 | Ceruloplasmin | 181 | EpCAM | 241 | GPR-39 |
| 2 | Positive-2a | 62 | ApoD | 122 | CFHR2 | 182 | EphA1 | 242 | GPX1 |
| 3 | Positive-3a | 63 | ApoM | 123 | Chemerin | 183 | EphA2 | 243 | GPX3 |
| 4 | Blank | 64 | ApoH | 124 | CHI3L1 | 184 | EphA3 | 244 | Pancreastatin |
| 5 | 11b-HSD1 | 65 | APP | 125 | Chromogranin A | 185 | EphA4 | 245 | GRP |
| 6 | 2B4 | 66 | ASPH | 126 | Chymase | 186 | EphA5 | 246 | GRP75 |
| 7 | 4-1BB | 67 | Attractin | 127 | ciAP-2 | 187 | EphA6 | 247 | GRP78 |
| 8 | ABL1 | 68 | B3GNT1 | 128 | Ck beta 8-1 | 188 | EphA7 | 248 | GSR |
| 9 | ACE | 69 | BAF57 | 129 | CK-MB | 189 | EphA8 | 249 | GST |
| 10 | ACE-2 | 70 | BAFF | 130 | Claudin-3 | 190 | EphB1 | 250 | HADHA |
| 11 | ACK1 | 71 | BAI-1 | 131 | Claudin-4 | 191 | EphB2 | 251 | HAI-1 |
| 12 | ACPP | 72 | BCAM | 132 | CLEC3B | 192 | EphB3 | 252 | HAI-2 |
| 13 | ACTH | 73 | Beta 2M | 133 | Clusterin | 193 | EphB4 | 253 | hCG alpha |
| 14 | ADAM-9 | 74 | Beta Defensin 4 | 134 | CNDP1 | 194 | EphB6 | 254 | hCgb |
| 15 | Neurokinin-A | 75 | Beta IG-H3 | 135 | Factor XIII A | 195 | ERRA | 255 | Hck |
| 16 | ADAMTS-1 | 76 | Biglycan | 136 | Factor XIII B | 196 | Erythropoietin R | 256 | HE4 |
| 17 | ADAMTS-L2 | 77 | BLAME | 137 | COCO | 197 | ESAM | 257 | Hemopexin |
| 18 | ADAMTS-4 | 78 | BMP-9 | 138 | C2 | 198 | EV15L | 258 | Hepcidin |
| 19 | ADAMTS-5 | 79 | BMX | 139 | C3a | 199 | EXTL2 | 259 | HSP32 |
| 20 | ADAMTS-10 | 80 | BNIP2 | 140 | C5/CSa | 200 | FABP1 | 260 | HOXA10 |
| 21 | ADAMTS-13 | 81 | Btk | 141 | C7 | 201 | FABP2 | 261 | Haptoglobin |
| 22 | ADAMTS-15 | 82 | ApoC1 | 142 | C8B | 202 | FABP4 | 262 | HSP10 |
| 23 | ADAMTS-17 | 83 | CA 9 | 143 | C9 | 203 | FAK | 263 | HSP20 |
| 24 | ADAMTS-18 | 84 | CA 15-3 | 144 | Complement factor H | 204 | FAP | 264 | HSP27 |
| 25 | ADAMTS-19 | 85 | CA 19-9 | 145 | Contactin-1 | 205 | Fc RIIB/C | 265 | HSP40 |
| 26 | Adipsin | 86 | CA 125 | 146 | Contactin-2 | 206 | Fen 1 | 266 | HSP60 |
| 27 | Afamin | 87 | Cadherin-13 | 147 | Corticosteroid-binding globulin | 207 | FER | 267 | HSP70 |
| 28 | AFP | 88 | Calbindin | 148 | COX-2 | 208 | Ferritin | 268 | HSP90 |
| 29 | ALBUMIN | 89 | Calbindin D | 149 | C-peptide | 209 | Fetuin A | 269 | HSPA8 |
| 30 | IL-36RN | 90 | Calcitonin | 150 | Creatinine | 210 | Fetuin B | 270 | HTRA2 |
| 31 | Aldolase A | 91 | Calreticulin | 151 | CRP | 211 | FGFR1 | 271 | IBSP |
| 32 | Aldolase B | 92 | Calsyntenin-1 | 152 | CRTAM | 212 | FGFR1 alpha | 272 | IGF2BP1 |
| 33 | Aldolase C | 93 | CPN2 | 153 | CSH1 | 213 | FGFR2 | 273 | IGFBP-5 |
| 34 | ALK | 94 | CART | 154 | gamma-Thrombin | 214 | Fibrinogen | 274 | IL-23p19 |
| 35 | Alpha Lactalbumin | 95 | Caspase-3 | 155 | CutA | 215 | Fibrinopeptide A | 275 | IL-33 |
| 36 | Alpha 1 AG | 96 | Caspase-8 | 156 | cTnT | 216 | Fibronectin | 276 | IL-34 |
| 37 | A1BG | 97 | Cathepsin B | 157 | Cyclin D1 | 217 | Ficolin-3 | 277 | INSRR |
| 38 | A1M | 98 | Cathepsin D | 158 | Cystatin A | 218 | FIH | 278 | Integrin alpha V |
| 39 | A2M | 99 | Cathepsin L | 159 | Cystatin B | 219 | FOLR1 | 279 | CD61 |
| 40 | TPM1 | 100 | Cathepsin S | 160 | Cystatin C | 220 | FOXP3 | 280 | Itk |
| 41 | ALPP | 101 | CBP | 161 | Cytochrome C | 221 | FoxO1 | 281 | ITM2B |
| 42 | pro-MMP13 | 102 | CCK | 162 | Cytokeratin 8 | 222 | FoxP3 | 282 | Kallikrein 2 |
| 43 | AMICA | 103 | CD23 | 163 | Cytokeratin 18 | 223 | FRK | 283 | ApoC3 |
| 44 | AMPKa1 | 104 | CD24 | 164 | Cytokeratin 19 | 224 | FSH | 284 | Kallikrein 5 |
| 45 | Amylin | 105 | CD36 | 165 | DBI | 225 | Furin | 285 | Kallikrein 6 |
| 46 | ANGPTL3 | 106 | CD38 | 166 | DCBLD2 | 226 | Fyn | 286 | Positive-1b |
| 47 | ANGPTL4 | 107 | CD44 | 167 | D-Dimer | 227 | GADD45A | 287 | Positive-2b |
| 48 | Annexin A7 | 108 | CD45 | 168 | DEFA1/3 | 228 | Galectin-1 | 288 | Positive-3b |
| 49 | APC | 109 | CD46 | 169 | Defensin | 229 | Galectin-3BP | 289 | neg |
| 50 | APCS | 110 | CD47 | 170 | Desmin | 230 | Galectin-7 | 290 | Kallikrein 7 |
| 51 | Apelin | 111 | CD55 | 171 | DLL1 | 231 | Gas1 | 291 | Kallikrein 8 |
| 52 | Apex1 | 112 | CD59 | 172 | DLL4 | 232 | Gastrin | 292 | Kallikrein 10 |
| 53 | APN | 113 | CD71 | 173 | DMP-1 | 233 | GATA-3 | 293 | Kallikrein 11 |
| 54 | ApoA1 | 114 | CD74 | 174 | DPPIV | 234 | GATA-4 | 294 | Kallikrein 14 |
| 55 | ApoA2 | 115 | CD90 | 175 | BNP | 235 | Gelsolin | 295 | KCC3 |
| 56 | ApoA4 | 116 | CD97 | 176 | E-Cadherin | 236 | Ghrelin | 296 | KCTD10 |
| 57 | ApoB | 117 | CD 79 alpha | 177 | Endorphin Beta | 237 | GLP-1 | 297 | KIF3B |
| 58 | ApoC2 | 118 | CD200 | 178 | Endothelin Receptor A | 238 | GPI | 298 | KLF4 |
| 59 | ApoB100 | 119 | CEA | 179 | Enolase 2 | 239 | GPBB | 299 | LAG-3 |
| 60 | ApoE | 120 | CEACAM-1 | 180 | ENPP2 | 240 | GMNN | 300 | pro-Glucagon |

RayBio® Human Antibody Array L-493 Target List ...continued

| Number | Name | Number | Name | Number | Name | Number | Name |
|--------|----------------|--------|------------------------|--------|--------------------|--------|-------------------------------|
| 301 | Layilin | 361 | Pappalysin-1 | 421 | S100A4 | 481 | TRPC6 |
| 302 | LDL R | 362 | Pancreatic Polypeptide | 422 | S100A6 | 482 | TRPM7 |
| 303 | Legumain | 363 | Presenilin 1 | 423 | S100A8 | 483 | Trypsin 1 |
| 304 | LH | 364 | PARK7 | 424 | S-100b | 484 | TSH |
| 305 | LIMPII | 365 | Visfatin | 425 | SART1 | 485 | TSLP |
| 306 | LIN41 | 366 | P-Cadherin | 426 | SART3 | 486 | TXK |
| 307 | Livin | 367 | PCAF | 427 | SCG3 | 487 | Uromodulin |
| 308 | LOX-1 | 368 | PD-1 | 428 | Selenoprotein P | 488 | TFF1 |
| 309 | LPS | 369 | PTH | 429 | SEMA3A | 489 | VDUP-1 |
| 310 | LRG1 | 370 | Troponin C | 430 | Serotonin | 490 | VEGF R1 |
| 311 | LTF | 371 | PDX-1 | 431 | Serpin A1 | 491 | VEGF |
| 312 | LTK | 372 | PEDF | 432 | Serpin A12 | 492 | VIP Receptor 2 |
| 313 | Lumican | 373 | PEPSINOGEN I | 433 | Serpin A3 | 493 | Vitamin D Receptor |
| 314 | Lyn | 374 | PEPSINOGEN II | 434 | Serpin A4 | 494 | Vitamin D-BP |
| 315 | LYRIC | 375 | Vasopressin | 435 | Serpin A5 | 495 | Vitamin K-dependent protein S |
| 316 | LYVE-1 | 376 | PGRP-5 | 436 | Serpin A8 | 496 | Vitronectin |
| 317 | LZTS1 | 377 | PI 16 | 437 | Serpin A9 | 497 | VWF |
| 318 | Mammaglobin A | 378 | PI 3Kinase p85 beta | 438 | Serpin B5 | 498 | Wilms Tumor 1 |
| 319 | Marapsin | 379 | PIM2 | 439 | Serpin D1 | 499 | XIAP |
| 320 | MATK | 380 | PKM2 | 440 | Serpin I1 | 500 | ZAG |
| 321 | MBL | 381 | Plasminogen | 441 | SERPING1 | 501 | ZAP70 |
| 322 | MBL-2 | 382 | Podocalyxin | 442 | SERTAD2 | 502 | Neg |
| 323 | Mer | 383 | POMC | 443 | SHBG | 503 | Neg |
| 324 | Mesothelin | 384 | PON1 | 444 | SMAC | 504 | Neg |
| 325 | MICB | 385 | PON2 | 445 | SNCG | 505 | Neg |
| 326 | Midkine | 386 | PPARg2 | 446 | SSTR5 | 506 | Neg |
| 327 | MINA | 387 | PPP2R5C | 447 | Somatotropin | 507 | Neg |
| 328 | FABP3 | 388 | NR3C3 | 448 | SOST | 508 | Positive-3c |
| 329 | MSHa | 389 | INSL3 | 449 | SOX17 | 509 | Positive-2c |
| 330 | MTUS1 | 390 | Pro-BDNF | 450 | SOX2 | 510 | Positive-1c |
| 331 | Myoglobin | 391 | Procalcitonin | 451 | SPARCL1 | | |
| 332 | NAIP | 392 | Pro-Cathepsin B | 452 | SPINK1 | | |
| 333 | Nanog | 393 | Thrombin | 453 | SRMS | | |
| 334 | NELL2 | 394 | Prohibitin | 454 | SSEA-1 | | |
| 335 | NEP | 395 | ProSAAS | 455 | SSEA-4 | | |
| 336 | Galanin | 396 | Prostasin | 456 | SSTR2 | | |
| 337 | Nesfatin | 397 | PSP | 457 | Survivin | | |
| 338 | Nestin | 398 | Pro-MMP-7 | 458 | SYK | | |
| 339 | NET1 | 399 | Pro-MMP-9 | 459 | Syndecan-1 | | |
| 340 | Netrin G2 | 400 | Protein p65 | 460 | Syndecan-3 | | |
| 341 | Netrin-4 | 401 | PSA-Free | 461 | TACE | | |
| 342 | Neuropeptide Y | 402 | PSA-total | 462 | TAF4 | | |
| 343 | NF1 | 403 | PTHLP | 463 | Tyk2 | | |
| 344 | NM23-H1/H2 | 404 | PTN | 464 | Tec | | |
| 345 | Presenilin 2 | 405 | PTPRD | 465 | TFF3 | | |
| 346 | Notch-1 | 406 | PYK2 | 466 | Thrombomodulin | | |
| 347 | NPTX1 | 407 | PYY | 467 | Thymidine Kinase-1 | | |
| 348 | NPTXR | 408 | Ras | 468 | Thyroglobulin | | |
| 349 | Progesterone | 409 | RBP4 | 469 | TIM-1 | | |
| 350 | Ntn1 | 410 | RECK | 470 | TNK1 | | |
| 351 | OCT3/4 | 411 | RELM alpha | 471 | TOPORS | | |
| 352 | Omentin | 412 | Resistin | 472 | TPA | | |
| 353 | Osteocalcin | 413 | RET | 473 | TRA-1-60 | | |
| 354 | Osteopontin | 414 | RIP1 | 474 | TRA-1-81 | | |
| 355 | OX40 | 415 | ROCK1 | 475 | Transferrin | | |
| 356 | p21 | 416 | ROCK2 | 476 | Trappin-2 | | |
| 357 | p27 | 417 | ROR1 | 477 | TRKB | | |
| 358 | p53 | 418 | ROR2 | 478 | TROPONIN I | | |
| 359 | PAI-1 | 419 | ROS | 479 | TYRO10 | | |
| 360 | PAK7 | 420 | RYK | 480 | TRPC1 | | |

VI. Interpretation of Results:

A. Explanation of Controls Spots


- 1) Positive Control spots (POS1, POS2, POS3) are standardized amounts of biotinylated IgGs printed directly onto the array. All other variables being equal, the Positive Control intensities will be the same for each sub-array. This allows for normalization based upon the relative fluorescence signal responses to a known control, much as “housekeeping” genes or proteins are used to normalize results in PCR or Western blots, respectively.
- 2) Negative Control (NEG) spots contain a protein-containing buffer (used to dilute antibodies printed on the array). Their signal intensities represent non-specific binding of the Cy3-Conjugated Streptavidin. Negative control signal intensities are usually very close to background signals in each sub-array.

B. Typical Results


The following figure shows the RayBio® L-Series Human Antibody Array 1000 probed with a serum sample. The images were captured using a Axon GenePix laser scanner. The strong signals in row 20 and the upper left and lower right corners of each array are Positive Controls, which can be used to identify the orientation and help normalize the results between arrays.

RayBio® L-series Human Antibody Array 507

Sample-1




Sample-2




RayBio® L-series Human Antibody Array L-493

Sample-1



Sample-2



If scanned using optimal settings, 3 distinct signal intensities will be seen: POS1>POS2>POS3. If all of these signals are of similar intensity, try increasing or decreasing laser power and/or signal gain settings.

Note: In the absence of an external standard curve for each protein detected, there is no means of assessing absolute or relative concentrations of different proteins in the same sample using immunoassays. If you wish to obtain quantitative data (ie, concentrations of the various analytes in your samples), try using our Quantibody® Arrays as a targeted follow up experiment.

C. Background Subtraction

Once you have obtained fluorescence intensity data, you should subtract the background and normalize to the Positive Control signals before proceeding to analysis.

Most laser fluorescence scanners' software have an option to automatically measure the local background around each spot. For best results, we recommend comparing signal intensities representing the MEDIAN background signals minus local background. If your resulting fluorescence signal intensity reports do not include these values (e.g., a column labeled as "MED532-B532"), you may need to subtract the background manually or change the default settings on your scanner's data report menu.

D. Normalization of Array Data

To normalize signal intensity data, one sub-array is defined as "reference" to which the other arrays are normalized. This choice is arbitrary. For example, in our Analysis Tool Software (described below), the array represented by data entered in the left-most column each worksheet is the default "reference array."

You can calculate the normalized values as follows:

$$X(Ny) = X(y) * P1/P(y)$$

Where:

P1 = mean signal intensity of POS spots on reference array

P(y) = mean signal intensity of POS spots on Array "y"

X(y) = mean signal intensity for spot "X" on Array "y"

X(Ny) = normalized signal intensity for spot "X" on Array "y"

The RayBio® Analysis Tool software is available for use with data obtained using RayBio® Biotin Label-based Antibody Arrays. You can copy and paste your signal intensity data (with and without background) into the Analysis Tool, and it will automatically normalize signal intensities to the Positive Controls.

To order the Analysis Tool, please contact us at +1-770-729-2992 or info@raybiotech.com for more information.

E. Threshold of Significant Difference

After subtracting background signals and normalization to Positive Controls, comparison of signal intensities between and among array images can be used to determine relative differences in expression levels of each protein between samples or groups.

Any ≥ 1.5 -fold increase or ≤ 0.65 -fold decrease in signal intensity for a single analyte between samples or groups may be considered a measurable and significant difference in expression, provided that both sets of signals are well above background (Mean background + 2 standard deviations, accuracy $\approx 95\%$).

VII. Troubleshooting Guide

| Problem | Cause | Recommendation |
|------------------------|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| Weak Signal | Inadequate detection | Increase laser power and PMT parameters |
| | Inadequate reagent volumes or improper dilution | Check pipettes and ensure correct preparation |
| | Short incubation time | Ensure sufficient incubation time and change sample incubation step to overnight |
| | Too low protein concentration in sample | Dilute starting sample less or concentrate sample |
| | Improper storage of kit | Store kit as suggested temperature. Don't freeze/thaw the slide. |
| Uneven signal | Bubble formed during incubation | Handle and pipette solutions more gently; De-gas solutions prior to use |
| | Arrays are not completely covered by reagent | Prepare more reagent and completely cover arrays with solution |
| | Reagent evaporation | Cover the incubation chamber with adhesive film during incubation |
| General | Cross-contamination from neighboring wells | Avoid overflowing wash buffer between wells |
| | Comet tail formation | Air dry the slide for at least 1 hour before usage |
| | Inadequate detection | Increase laser power so the highest standard concentration for each cytokine receives the highest possible reading yet remains unsaturated |
| High background | Overexposure | Lower the laser power |
| | Dark spots | Completely remove wash buffer in each wash step |
| | Insufficient wash | Increase wash time and use more wash buffer |
| | Dust | Minimize dust in work environment before starting experiment |
| | Slide is allowed to dry out | Take additional precautions to prevent slides from drying out during experiment |

VIII. Selected References

Christina Scheel et al., *Paracrine and Autocrine Signals Induce and Maintain Mesenchymal and Stem Cell States in the Breast*. *Cell*. 2011;145, 926–940

Lin Y, Huang R, Chen L, et al., *Profiling of cytokine expression by biotin-labeled-based protein arrays*. *Proteomics*. 2003, 3: 1750–1757.

Huang R, Jiang W, Yang J, et al., *A Biotin Label-based Antibody Array for High-content Profiling of Protein Expression*. *Cancer Genomics Proteomics*. 2010; 7(3):129–141.

Liu T, Xue R, Dong L, et al., *Rapid determination of serological cytokine biomarkers for hepatitis B–virus-related hepatocellular carcinoma using antibody arrays*. *Acta Biochim Biophys Sin*. 2011; 43(1):45–51.

Cui J, Chen Y, Chou W-C, et al., *An integrated transcriptomic and computational analysis for biomarker identification in gastric cancer*. *Nucl Acids Res*. 2011; 39(4):1197–1207.

Jun Zhong et al., *Temporal Profiling of the Secretome during Adipogenesis in Humans*. *Journal of Proteome Research*. 2010, 9, 5228–5238

Chowdury UR, Madden BJ, Charlesworth MC, Fautsch MP., *Proteomic Analysis of Human Aqueous Humor*. *Invest Ophthalmol Visual Sci*. 2010; 51(10):4921–4931.

Wei Y, Cui C, Lainscak M, et al., *Type-specific dysregulation of matrix metalloproteinases and their tissue inhibitors in end-stage heart failure patients: relationship between MMP-10 and LV remodeling*. *J Cell Mol Med*. 2011; 15(4):773–782.

Kuranda K, Berthon C, Lepêtre F, et al., *Expression of CD34 in hematopoietic cancer cell lines reflects tightly regulated stem/progenitor-like state*. *J Cell Biochem*. 2011; 112(5):1277–1285.

Toh HC, Wang W-W, Chia WK, et al., *Clinical Benefit of Allogenic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients*. *Clin Chem Res*. 2009; 15:7726–7736.

Zhen Hou, *Cytokine array analysis of peritoneal fluid between women with endometriosis of different stages and those without endometriosis*. Biomarkers. 2009;14(8): 604-618.

Yao Liang Tang, et al., *Hypoxic Preconditioning Enhances the Benefit of Cardiac Progenitor Cell Therapy for Treatment of Myocardial Infarction by Inducing CXCR4*. Circ Res. 2009;109:197723

RayBio® L-series Antibody Arrays are patent-pending technology developed by RayBiotech.

This product is intended for research only and is not to be used for clinical diagnosis. Our products may not be resold, modified for resale, or used to manufacture commercial products without written approval by RayBiotech, Inc.


Under no circumstances shall RayBiotech be liable for any damages arising out of the use of the materials.

Products are guaranteed for six months from the date of shipment when handled and stored properly. In the event of any defect in quality or merchantability, RayBiotech's liability to buyer for any claim relating to products shall be limited to replacement or refund of the purchase price.

RayBio® is a registered trademark of RayBiotech, Inc.

GenePix® is a registered trademark of Molecular Devices, Inc.

This product is for research use only.



©2011 RayBiotech, Inc.